For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of CorMedix Inc (NASDAQ: CRMD) was $10.91 for the day, up 5.61% from the previous closing price of $10.33. In other words, the price has increased by $5.61 from its previous closing price. On the day, 1.01 million shares were traded. CRMD stock price reached its highest trading level at $10.92 during the session, while it also had its lowest trading level at $10.32.
Ratios:
Our analysis of CRMD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.96. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 26, 2024, initiated with a Buy rating and assigned the stock a target price of $13.
On August 10, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $6.
On February 17, 2021, Needham started tracking the stock assigning a Buy rating and target price of $31.Needham initiated its Buy rating on February 17, 2021, with a $31 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 14 ’24 when Hurlburt Elizabeth sold 140,027 shares for $11.18 per share. The transaction valued at 1,565,670 led to the insider holds 45,397 shares of the business.
Hurlburt Elizabeth bought 140,027 shares of CRMD for $1,556,416 on Nov 14 ’24. On Mar 13 ’24, another insider, Todisco Joseph, who serves as the Chief Executive Officer of the company, bought 13,561 shares for $3.74 each. As a result, the insider paid 50,718 and bolstered with 352,839 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 661988224 and an Enterprise Value of 581322432. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.71 while its Price-to-Book (P/B) ratio in mrq is 10.76. Its current Enterprise Value per Revenue stands at 47.408 whereas that against EBITDA is -11.451.
Stock Price History:
Over the past 52 weeks, CRMD has reached a high of $13.85, while it has fallen to a 52-week low of $2.89. The 50-Day Moving Average of the stock is 13.31%, while the 200-Day Moving Average is calculated to be 86.10%.
Shares Statistics:
CRMD traded an average of 1.16M shares per day over the past three months and 1254360 shares per day over the past ten days. A total of 60.68M shares are outstanding, with a floating share count of 59.76M. Insiders hold about 1.51% of the company’s shares, while institutions hold 31.40% stake in the company. Shares short for CRMD as of 1730332800 were 6284633 with a Short Ratio of 5.42, compared to 1727654400 on 9268532. Therefore, it implies a Short% of Shares Outstanding of 6284633 and a Short% of Float of 10.37.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of CorMedix Inc (CRMD).The consensus estimate for the next quarter is $0.15, with high estimates of $0.15 and low estimates of $0.15.
Analysts are recommending an EPS of between -$0.49 and -$0.54 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is $0.45, with 4.0 analysts recommending between $0.94 and $0.03.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $31.02M. There is a high estimate of $31.02M for the next quarter, whereas the lowest estimate is $31.02M.
Based on 4 analysts’ estimates, the company’s revenue will be $110.72M in the next fiscal year. The high estimate is $132.4M and the low estimate is $87.26M.
